GFAP and age-related macular degeneration: Our results focusing on the diseased AMD cerebellum indicate that neonatal AAV6 treatment also markedly ameliorates reactive astroglial response (GFAP) and reduces lysosomal storage (LAMP1) compared to untreated AMD mice.